Cytotoxic factors for modulating cell death

Details Cytotoxic factors for modulating cell death Cytotoxic factors for modulating cell death

2006-08-01

2006-08-01

Yu, Misook (Department: 1642)

Perfume compositions

Perfume compositions

With preservative, stabilizer, or fixative

Reexamination Certificate

active

07084105

ABSTRACT:
Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death. The present inventors have found that different pathogens produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.

REFERENCES:
patent: 5681810 (1997-10-01), Villemez et al.
patent: 5789389 (1998-08-01), Tarasewicz
patent: 5972899 (1999-10-01), Zychlinsky et al.
Voet et al., (Biochemistry, 1990, John Wiley & Sons, pp. 415-417, 932, and 933 only).
Definition of “necrosis” as “to make dead” according to Merriam-Webster Online dictionary downloaded from URL>>www.m-w.com on Apr. 25, 2005.
Zaborina, O. et al., “P2Z independent and P2Z receptor mediated macrophage killing byP. aeruginosaisolated from cystic fibrosis patients”, Infect Immun. 67: 5231-5242 (1999).
Melnikov, A. et al., “Clinical and environmental isolates ofBurkholderia cepaciaexhibit differential cytotoxicity towards macrophages and mast cells”, Mol. Microbiol. 36: 1481-1493 (2000).
Punj, V. et al., “Phagocytic cell killing mediated by secreted cytotoxic factors ofVibrio cholerae”, Infect. Immun. 68: 4930-4937 (2000).
Zaborina, O. et al., “Secreted products of a nonmucoidPseudomonas aeruginosastrain induce two modes of macrophage killing: external ATP-dependent, P2Z-receptor-mediated necrosis and ATP-independent, caspase-mediated apoptosis”, Microbiology 146: 2521-2530 (2000).
Kirn, David H. et al., “Replication-selective microbiological agents fighting cancer with targeted germ warfare”, The Journal of Clinical Investigation, vol. 105, No. 7, 837-839 (2000).
Sznol, Mario et al., “Use of Preferentially Replicating Bacteria for the Treatment of Cancer”, The Journal of Clinical Investigation, vol. 105, No. 8, 1027-1030 (2000).
Pawelek, John H. et al., “Tumor-targetedSalmonellaas a Novel Anticancer Vector”, Cancer Research, vol. 57, 4537-4544 (1997).
Potera, Carol, “HarnessingSalmonella'sPositive Powers against Tumors”, ASM News, vol. 66, No. 6 (2000).
Alexandroff, Anton B. et al., “BCG immunotherapy of bladder cancer: 20 years on”, The Lancet, vol. 353, 1689-1694 (May 15, 1999).
O'Donnell, Michael A., “The genetic reconstruction of BCG as a new immunotherapeutic tool”, Tibtech, vol. 15, 512-517 (Dec. 1997).
Paglia, Paola et al., “Keeping the immune system alerted against cancer”, Cancer Immunol. Immunother., 46:88-92 (1998).
Hunter, Christopher A. et al., “Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis”, The Journal of Immunology, 166: 5878-5881 (2001).
L. H. Dang et al., “Combination bacteriolytic therapy for the treatment of experimental tumors.” Proc. Nat. Acad. Sci. USA, 98, 15155-15160 (2001).
R. K. Jain and N. S. Forbes, “Can engineered bacteria help control cancer?” Proc. Natl. Acad. Sci. USA, 98, 14748-14750 (2001).
A. W. Confer and Janet A. Durham, Am. J. Res., vol. 53, No. 5, pp. 646-652 (1992).
T. Wu et al., Antimicrobial: Agents and Chemotheraphy, vol. 44, No. 5, pp. 1200-1208 (May 2000).
PCT International Application No. PCT/US02/01408—International Search Report.
M. Kukimoto et al., FEBS Letters, 394, pp. 87-90 (1996).
F. Cutruzzola et al., J. Inorganic Chemistry, 88, pp. 353-361 (2002).
L. M. Murphy et al., J. Mol. Biol., 315, pp. 859-871 (2002).
V Punj & A. M. Chakrabarty, Cellular Microbiology, 5(4), pp. 225-231 (2003).
T Yamada et al., PNAS, vol. 99, No. 22, pp. 14098-14103 (2002).
T. Yamada et al., Infection & Immunity, vol. 70, No. 12, pp. 7054-7062 (2002).
M. Goto et al., Mol. Bio., 47(2), pp. 549-559 (2003).
V. Punj et al., Biochemical and Biophysical Research Communications, vol. 312, pp. 109-114 (2003).
Vasu Punj et al., Oncogene 2003—Proof copy.
Vasu Punj et al., “Bacterial Cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer”, Oncogene (2004) 23, 2367-78.
Zaborina et al., “Secretion of ATP-utilizing enzymes, nucleoside diphosphate kinase and ATPase, byMycobacterium bovisBCG: sequestration of ATP from macrophase P2Z receptors?”, Molecular Microbiology (1999) 31(5), 1333-1343.
Anomymous: “Plastocyanin precursor” Database EMBL Online!, Nov. 1, 1997, XP002306632 abstract.
Anomymous: “Rusticyanin precursor” Database EMBL Online!, Mar. 1, 1992, XP002306633 abstract.
Anonymous: “Pseudoazurin precursor” Database EMBL Online!, Feb. 1, 1991, XP002306634 abstract.

Affiliated with

Also associated with

Rating

Cytotoxic factors for modulating cell death does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytotoxic factors for modulating cell death, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic factors for modulating cell death will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3715315